Terms: = Lung cancer AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884
440 results:
1. The incorporation of acetylated LAP-TGF-β1 proteins into exosomes promotes TNBC cell dissemination in lung micro-metastasis.
Yu P; Han Y; Meng L; Tang Z; Jin Z; Zhang Z; Zhou Y; Luo J; Luo J; Han C; Zhang C; Kong L
Mol Cancer; 2024 Apr; 23(1):82. PubMed ID: 38664722
[TBL] [Abstract] [Full Text] [Related]
2. Tracing genetic diversity captures the molecular basis of misfolding disease.
Zhao P; Wang C; Sun S; Wang X; Balch WE
Nat Commun; 2024 Apr; 15(1):3333. PubMed ID: 38637533
[TBL] [Abstract] [Full Text] [Related]
3. A pH-responsive nanoplatform with dual-modality imaging for enhanced cancer phototherapy and diagnosis of lung metastasis.
Yuan M; Han Z; Li Y; Zhan X; Sun Y; He B; Liang Y; Luo K; Li F
J Nanobiotechnology; 2024 Apr; 22(1):180. PubMed ID: 38622591
[TBL] [Abstract] [Full Text] [Related]
4. High-content analysis identified synergistic drug interactions between INK128, an mTOR inhibitor, and HDAC inhibitors in a non-small cell lung cancer cell line.
Wang S; Oliveira-Silveira J; Fang G; Kang J
BMC Cancer; 2024 Mar; 24(1):335. PubMed ID: 38475728
[TBL] [Abstract] [Full Text] [Related]
5. hsp90: A promising target for NSCLC treatments.
Zhu Y; Dai Z
Eur J Pharmacol; 2024 Mar; 967():176387. PubMed ID: 38311278
[TBL] [Abstract] [Full Text] [Related]
6. Prospects and challenges of noncoding-RNA-mediated inhibition of heat shock protein 90 for cancer therapy.
Mattoo S; Gupta A; Chauhan M; Agrawal A; Pore SK
Biochim Biophys Acta Gene Regul Mech; 2024 Mar; 1867(1):195006. PubMed ID: 38218528
[TBL] [Abstract] [Full Text] [Related]
7. Identification of molecular subtypes and prognostic model to reveal immune infiltration and predict prognosis based on immunogenic cell death-related genes in lung adenocarcinoma.
Dong Y; Yu X; Song H; Chen Q; Zheng B; Ji X; Xu M; Liu J; Sun X; Wang Q; Ren R; Lu H
Cell Cycle; 2023; 22(23-24):2566-2583. PubMed ID: 38164943
[TBL] [Abstract] [Full Text] [Related]
8. Hsp Inhibitor is Affective Against Adenocarcinomic Human Alveolar Basal Epithelial Cells Through Modulating ERK/MAPK Signaling Pathway.
Tunoğlu S; Tutar L; Gümüş M; Tunoğlu ENY; Koca İ; Tutar Y
Chem Biodivers; 2024 Feb; 21(2):e202301422. PubMed ID: 38156745
[TBL] [Abstract] [Full Text] [Related]
9. JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.
Lu X; Yu R; Li Z; Yang M; Dai J; Liu M
Cancer Lett; 2024 Feb; 582():216517. PubMed ID: 38101609
[TBL] [Abstract] [Full Text] [Related]
10. Inhibition of hsp90 in Driver Oncogene-Defined lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy.
Marrugal Á; Ferrer I; Quintanal-Villalonga Á; Ojeda L; Pastor MD; García-Luján R; Carnero A; Paz-Ares L; Molina-Pinelo S
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762133
[TBL] [Abstract] [Full Text] [Related]
11. Integrated bioinformatics analysis of microarray data from non-small cell lung cancer.
Feng L; Cai W; Jin S; Chun C; Wang C; Ma L; Peng H; Dong X; Jiang J; Lu X; Pang L
Cell Mol Biol (Noisy-le-grand); 2023 Jul; 69(7):218-224. PubMed ID: 37715441
[TBL] [Abstract] [Full Text] [Related]
12. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
[TBL] [Abstract] [Full Text] [Related]
13. An Overview of Recent Findings that Shed Light on the Connection between Fat and cancer.
Pandit P; Shirke C; Bhatia N; Godad A; Belemkar S; Patel J; Zine S
Endocr Metab Immune Disord Drug Targets; 2024; 24(2):178-193. PubMed ID: 37489790
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathological and prognostic significance of SMAD4 in non-small cell lung cancer: A meta-analysis and database validation.
Li Z; Huang Y; Zhou R; Li Z; Yan Q
Medicine (Baltimore); 2023 Jul; 102(29):e34312. PubMed ID: 37478236
[TBL] [Abstract] [Full Text] [Related]
15. The p23 co-chaperone is a succinate-activated COX-2 transcription factor in lung adenocarcinoma tumorigenesis.
Yu Z; Peng Y; Gao J; Zhou M; Shi L; Zhao F; Wang C; Tian X; Feng L; Huo X; Zhang B; Liu M; Fang D; Ma X
Sci Adv; 2023 Jun; 9(26):eade0387. PubMed ID: 37390202
[TBL] [Abstract] [Full Text] [Related]
16. Network pharmacology and bioinformatics analysis identifies potential therapeutic targets of
Wu WY; Jiao X; Song WX; Wu P; Xiao PQ; Huang XF; Wang K; Zhan SF
Front Endocrinol (Lausanne); 2023; 14():1187882. PubMed ID: 37347115
[TBL] [Abstract] [Full Text] [Related]
17. Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression.
Wang S; Zhou L; Ji N; Sun C; Sun L; Sun J; Du Y; Zhang N; Li Y; Liu W; Lu W
Drug Resist Updat; 2023 Jul; 69():100976. PubMed ID: 37210811
[TBL] [Abstract] [Full Text] [Related]
18. TTT (Tel2-Tti1-Tti2) Complex, the Co-Chaperone of PIKKs and a Potential Target for cancer Chemotherapy.
Bhadra S; Xu YJ
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175973
[TBL] [Abstract] [Full Text] [Related]
19. Network pharmacology and molecular docking combined with widely targeted metabolomics to elucidate the potential compounds and targets of Euphorbia helioscopia seeds for the treatment of pulmonary fibrosis.
Liu Y; Sun W; Shen N; Hao W; Xin H; Che F; Cui Y
Comput Biol Med; 2023 Jun; 160():107007. PubMed ID: 37150086
[TBL] [Abstract] [Full Text] [Related]
20. EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
Elshatlawy M; Sampson J; Clarke K; Bayliss R
Mol Oncol; 2023 Jun; 17(6):950-963. PubMed ID: 37149843
[TBL] [Abstract] [Full Text] [Related]
[Next]
